NHPAP - National Healthcare Properties, Inc. - Preferred Stock (NasdaqGM) - Share Price and News

National Healthcare Properties, Inc. - Preferred Stock
US ˙ NasdaqGM ˙ US42226B2043

Overview
Healthcare Trust, Inc., based in the United States, is a real estate investment trust (REIT) primarily focused on acquiring, developing, owning, and managing high-quality healthcare-related properties. The company’s portfolio predominantly includes medical office buildings, seniors housing, and other healthcare-related facilities. A key aspect of Healthcare Trust's strategic approach involves leveraging long-term leases to maintain stable cash flows and minimize operational risks associated with its investments. Their preferred stock offering is an integral part of their capital structure, designed to attract investors seeking stable dividends while participating in the healthcare real estate market's growth potential. This financial instrument typically carries preferential rights in dividend payments and has implications for yield-focused investment strategies within the healthcare infrastructure sector.
Basic Stats

The share price of National Healthcare Properties, Inc. - Preferred Stock as of September 5, 2025 is $18.12 / share. This is a decrease of -0.11% from the prior week.

The Factor Analysis chart (below right) shows a view of National Healthcare Properties, Inc. - Preferred Stock from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.

For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.

Market Cap
EV
Shares Out. 28.30 MM
Earnings Date
EPS (TTM) -2.83
Dividend Yield 12.72 %
Ex-Dividend Date 2025-07-03
Borrow Rate 5.04
Short Shares Avail. 0.10 MM
Short Interest 0.01 MM
Short Float
Days to Cover 3.06 days
Risk Free Rate 4.17 %
Price Change (1 yr)
Volatility (1 yr) 0.20
Beta 0.70
Sharpe Ratio (1 yr)
Sortino Ratio (1 yr)
PE Ratio
Price/Book
Price/TBV
Book/Market
EBIT/EV
EBIT(3yr avg)/EV
ROA -0.04
ROE -0.10
ROIC -0.05
CROIC 0.01
OCROIC -0.06
Implied Volatility
Put/Call OI Ratio
Growth
Profitability
Quality Score
Value Score
Momentum Score
Stability (Low Vol) Score
Analyst Sentiment
Fund Sentiment
Insider Sentiment
Officer Sentiment
Dividend Score
QVM Score
Piotroski F-SCORE 3.00 /9
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Stock Upgrades/Downgrades

This card shows analyst upgrades/downgrades for National Healthcare Properties, Inc. - Preferred Stock. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.

The standard analyst ratings are generally as follows:
  • Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
  • Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
  • Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.

When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.

The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.

Date Analyst Prior Latest
Recommendation
Action
No data available.
Other Listings
DE:4ON €15.00
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista